U.S., April 19 -- ClinicalTrials.gov registry received information related to the study (NCT06934941) titled 'Phase 1 Single Ascending Dose Study' on April 03.
Brief Summary: Phase 1, double-blind, placebo-controlled, single-centre, single ascending dose escalation study to assess safety and tolerability of a monoclonal antibody, NM-101 in healthy volunteer subject and multiple system atrophy (MSA) patients.
Study Start Date: Nov. 25, 2024
Study Type: INTERVENTIONAL
Condition:
Healthy Subjects
Intervention:
DRUG: NM-101
NM-101 IV versus placebo
DRUG: Placebo
Placebo
Recruitment Status: RECRUITING
Sponsor: Neuramedy Co. Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....